Gut dysbacteriosis and intestinal disease: mechanism and treatment.
Meng X, Zhang G, Cao H, Yu D, Fang X, de Vos WM, Wu H.
J Appl Microbiol. 2020 Oct;129(4):787-805. doi: 10.1111/jam.14661. Epub 2020 May 19.
Salidroside alleviates ulcerative colitis via inhibiting macrophage pyroptosis and repairing the dysbacteriosis-associated Th17/Treg imbalance.
Liu X, Zhou M, Dai Z, Luo S, Shi Y, He Z, Chen Y.
Phytother Res. 2023 Feb;37(2):367-382. doi: 10.1002/ptr.7636. Epub 2022 Nov 4.
Introduction to the human gut microbiota.
Thursby E, Juge N.
Biochem J. 2017 May 16;474(11):1823-1836. doi: 10.1042/BCJ20160510.
Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction.
Drossman DA, Hasler WL.
Gastroenterology. 2016 May;150(6):1257-61. doi: 10.1053/j.gastro.2016.03.035.
Mechanisms and consequences of intestinal dysbiosis.
Weiss GA, Hennet T.
Cell Mol Life Sci. 2017 Aug;74(16):2959-2977. doi: 10.1007/s00018-017-2509-x. Epub 2017 Mar 28.
Gut microbiota and IBD: causation or correlation?
Ni J, Wu GD, Albenberg L, Tomov VT.
Nat Rev Gastroenterol Hepatol. 2017 Oct;14(10):573-584. doi: 10.1038/nrgastro.2017.88. Epub 2017 Jul 19.
Intestinal dysbacteriosis-induced IL-25 promotes development of HCC via alternative activation of macrophages in tumor microenvironment.
Li Q, Ma L, Shen S, Guo Y, Cao Q, Cai X, Feng J, Yan Y, Hu T, Luo S, Zhou L, Peng B, Yang Z, Hua Y.
J Exp Clin Cancer Res. 2019 Jul 11;38(1):303. doi: 10.1186/s13046-019-1271-3.
Eubiosis and dysbiosis: the two sides of the microbiota.
Iebba V, Totino V, Gagliardi A, Santangelo F, Cacciotti F, Trancassini M, Mancini C, Cicerone C, Corazziari E, Pantanella F, Schippa S.
New Microbiol. 2016 Jan;39(1):1-12.
The human gut microbiota: Metabolism and perspective in obesity.
Gomes AC, Hoffmann C, Mota JF.
Gut Microbes. 2018 Jul 4;9(4):308-325. doi: 10.1080/19490976.2018.1465157. Epub 2018 May 24.
Dysbiosis and the immune system.
Levy M, Kolodziejczyk AA, Thaiss CA, Elinav E.
Nat Rev Immunol. 2017 Apr;17(4):219-232. doi: 10.1038/nri.2017.7. Epub 2017 Mar 6.
